Request Information
Request Information
Event Specialty: Robotics
Meeting
Ashley McEvoy, Executive Vice President and Worldwide Chairman of Medical Devices at J&J came to Auris along with other key members of her team to personally welcome Auris into the Johnson & Johnson family, now that our acquisition has been finalized.
Ashley McEvoy also posted a public welcome through their social media channel on LinkedIn. McEvoy said that the acquisition of Auris will help bring J&J closer to its goal of disrupting medical innovation to provide improvements for patients, medical staff, and healthcare systems. J&J aims to build a digital ecosystem of robotics, advanced instrumentation, and data to improve patient outcomes.
McEvoy said Auris’ Monarch Platform will play a critical role in J&J’s Lung Cancer Initiative to prevent, detect, and cure the disease. J&J is focusing on lung cancer first because it is the leading cause of cancer deaths worldwide due to the fact that it is often not discovered until it is in the later stages. With the Monarch Platform, we are better equipped to detect and treat lung cancer in the earlier stages, which leads to better long-term outcomes for patients.
McEvoy also believes that Auris’ innovation will help J&J reimagine care for other diseases. “Our vision is a new era of digital surgery that will simplify procedures, drive efficiency, reduce complications and ultimately make surgery safer,” she said. The acquisition of Auris complements the work J&J is doing with other companies to serve patient needs.
Auris is proud to be a part of furthering J&J’s mission to “restore, enhance, and save the lives of more people.”
Read the post on LinkedInBronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.